The Role of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment of Heart Failure in Patients with Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.52914/apmp.v3i1.42Keywords:
type 2 diabetes mellitus, heart failure, diastolic dysfunction, sodium-glucose cotransporter-2 (SGLT2) inhibitorsAbstract
The current data on the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of heart failure in patients with type 2 diabetes mellitus are presented. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for the treatment of diabetes, have been shown to possess a favorable metabolic profile and to significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and total mortality, and progression of chronic kidney disease. Although initially considered to be only glucose-lowering agents, the effects of SGLT2i have expanded far beyond that, and their use is now being studied in the treatment of heart failure and chronic kidney disease, even in patients without diabetes. It is therefore critical for cardiologists, diabetologists, nephrologists, and primary care physicians to be familiar with this drug class.
References
Global report on diabetes. WHO Press, World Health Organization, Geneva, Switzerland, 2020, 88 pp. [https:// www.who.int/news-room/fact-sheets/detail/diabetes.
Центр медичної статистики МОЗ України. – Режим доступу www.medstat.gov.ua.
Н. Б. Зелінська, К. В. Грищенко, Є. В. Глоба. Цукровий діабет 2 типу у дітей та підлітків в світі і в Україні. //Український журнал дитячої ендокринології.—2021.—№1.—С.4—16. http://doi.org/10.30978/UJPE2021-1-4 DOI: https://doi.org/10.30978/UJPE2021-1-4
Зелінська Н.Б., Глоба Є.В., Руденко Н.Г. та ін. Дитяча ендокринологія в Україні. Аналіз показників надання спеціалізованої допомоги дітям у 2019 році //Український журнал дитячої ендокринології. — 2020. — № 1 (33). — С. 5—17. doi: 10.30978/UJPE2020-1-5. DOI: https://doi.org/10.30978/UJPE2020-1-5
Pankiv VI. Diabetes mellitus: definition, classification, epidemiology, risk factors. Mìžnarodnij endokrinologìčnij žurnal. 2013;7(55):95-104. doi: 10.22141/2224- 0721.7.55.2013.84685. DOI: https://doi.org/10.22141/2224-0721.7.55.2013.84685
Elliott P., Andersson B., Arbustini E. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008. Vol. 29. Р. 270-276. DOI: https://doi.org/10.1093/eurheartj/ehm342
Ernande L., Derumeaux G. Diabetic cardiomyopathy: Myth or reality? Archives of Cardiovascular Diseases. 2012. Vol. 105 (4). Р. 218–225. DOI: https://doi.org/10.1016/j.acvd.2011.11.007
Lehrke N. M., Diabetes Mellitus and Heart Failure. The American Journal of Cardiology. 2017. Vol. 120 (10). Suppl. Р. S37–S4. DOI: https://doi.org/10.1016/j.amjcard.2017.05.014
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guide - lines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI: https://doi.org/10.1093/eurheartj/ehz486
van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18:242-252. DOI: https://doi.org/10.1002/ejhf.483
Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги. Цукровий діабет 2 типу. Чинний. ГС 2012-1118.
Медична газета «Здоров’я України 21 сторіччя» № 10 (503), 2021 р. cт. 42-43.
Packer M, Anker SD, Butler J et al., for the EMPERORReduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. NEJM. 2020; August 29 [ahead of print] doi: 10.1056/NEJMoa2022190. DOI: https://doi.org/10.1056/NEJMoa2022190
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90- 100. DOI: https://doi.org/10.1177/1479164114559852
Writing Committee, Das SR, Everett BM, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee [published online ahead of print, 2020 Jul 28]. J Am Coll Cardiol. 2020; S0735- 1097(20)35391-2.
Zinman B, Wanner C, Lachin JM, et al; for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. DOI: https://doi.org/10.1056/NEJMoa1504720
Fitchett D, Zinman B, Wanner C, et al; the EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME. Eur Heart J. 2016;37:1526-1534. DOI: https://doi.org/10.1093/eurheartj/ehv728
Kosiborod M, Cavender MA, Fu AZ, et al; on behalf of the CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SodiumGlucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249-259. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.029190
Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial [published correction appears in Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20]. Lancet Diabetes Endocrinol. 2019;7(8):606-617. doi: 10.1016/S2213- 8587(19)30180-9.
Вацеба Т. С., Скрипник Н. В. Вплив варіабельності глікемії на компенсацію цукрового діабету https://doi.org/10.21856/j-PEP.2019.2.02 //Проблеми ендокринної патології — 2019. — № 2 (68). — С. 13—19.
Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494-510. https://doi.org/10.14341/DM8216 DOI: https://doi.org/10.14341/DM8216
Mìžnarodnij endokrinologìčnij žurnal. 2021;17(4):293-303. doi: 10.22141/2224-0721.17.4.2021.237342 DOI: https://doi.org/10.22141/2224-0721.17.4.2021.237342
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Tetiana Hradyk, Alina Tsysnetska
This work is licensed under a Creative Commons Attribution 4.0 International License.
